Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649
PURPOSE: In CheckMate 649, first-line nivolumab plus chemotherapy prolonged overall survival versus chemotherapy in patients with advanced/metastatic non-human epidermal growth factor receptor 2 (HER2)-positive gastric/gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC). We present exploratory patient-reported outcomes (PROs).
METHODS: In patients (N = 1,581) concurrently randomly assigned 1:1 to nivolumab plus chemotherapy or chemotherapy and in those with tumor PD-L1 expression at a combined positive score (CPS) of ≥5, health-related quality of life (HRQoL) was assessed using the EQ-5D and Functional Assessment of Cancer Therapy-Gastric (FACT-Ga), which included the FACT-General (FACT-G) and Gastric Cancer subscale (GaCS). The FACT-G GP5 item assessed treatment-related symptom burden. Longitudinal changes in HRQoL were assessed using mixed models for repeated measures in the PRO analysis population (randomly assigned patients with baseline and ≥1 postbaseline assessments). Time to symptom or definitive deterioration analyses were also conducted.
RESULTS: In the PRO analysis population (n = 1,360), PRO questionnaire completion rates were mostly >80% during treatment. Patient-reported symptom burden was not increased with nivolumab plus chemotherapy versus chemotherapy. Mean improved changes from baseline were greater with nivolumab plus chemotherapy versus chemotherapy for FACT-Ga total, GaCS, and EQ-5D visual analog scale in patients with a CPS of ≥5; results were similar for the overall PRO analysis population. In CPS ≥5 and all randomly assigned populations, nivolumab plus chemotherapy reduced the risk of symptom deterioration versus chemotherapy, on the basis of FACT-Ga total score and GaCS; time to definitive deterioration was longer, and the risk of definitive deterioration in HRQoL was reduced with nivolumab plus chemotherapy across EQ-5D and most FACT-Ga measures (hazard ratio [95% CI] <1).
CONCLUSION: Compared with chemotherapy alone, first-line nivolumab plus chemotherapy showed stable or better on-treatment HRQoL in patients with advanced/metastatic non-HER2-positive GC/GEJC/EAC and also showed decreased risk of definitive HRQoL deterioration.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
---|---|
Enthalten in: |
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 41(2023), 35 vom: 10. Dez., Seite 5388-5399 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Moehler, Markus [VerfasserIn] |
---|
Links: |
---|
Themen: |
31YO63LBSN |
---|
Anmerkungen: |
Date Completed 11.12.2023 Date Revised 16.02.2024 published: Print-Electronic ClinicalTrials.gov: NCT02872116 Citation Status MEDLINE |
---|
doi: |
10.1200/JCO.23.00170 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM362107998 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM362107998 | ||
003 | DE-627 | ||
005 | 20240216232624.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1200/JCO.23.00170 |2 doi | |
028 | 5 | 2 | |a pubmed24n1295.xml |
035 | |a (DE-627)NLM362107998 | ||
035 | |a (NLM)37713657 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Moehler, Markus |e verfasserin |4 aut | |
245 | 1 | 0 | |a Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649 |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 11.12.2023 | ||
500 | |a Date Revised 16.02.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a ClinicalTrials.gov: NCT02872116 | ||
500 | |a Citation Status MEDLINE | ||
520 | |a PURPOSE: In CheckMate 649, first-line nivolumab plus chemotherapy prolonged overall survival versus chemotherapy in patients with advanced/metastatic non-human epidermal growth factor receptor 2 (HER2)-positive gastric/gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC). We present exploratory patient-reported outcomes (PROs) | ||
520 | |a METHODS: In patients (N = 1,581) concurrently randomly assigned 1:1 to nivolumab plus chemotherapy or chemotherapy and in those with tumor PD-L1 expression at a combined positive score (CPS) of ≥5, health-related quality of life (HRQoL) was assessed using the EQ-5D and Functional Assessment of Cancer Therapy-Gastric (FACT-Ga), which included the FACT-General (FACT-G) and Gastric Cancer subscale (GaCS). The FACT-G GP5 item assessed treatment-related symptom burden. Longitudinal changes in HRQoL were assessed using mixed models for repeated measures in the PRO analysis population (randomly assigned patients with baseline and ≥1 postbaseline assessments). Time to symptom or definitive deterioration analyses were also conducted | ||
520 | |a RESULTS: In the PRO analysis population (n = 1,360), PRO questionnaire completion rates were mostly >80% during treatment. Patient-reported symptom burden was not increased with nivolumab plus chemotherapy versus chemotherapy. Mean improved changes from baseline were greater with nivolumab plus chemotherapy versus chemotherapy for FACT-Ga total, GaCS, and EQ-5D visual analog scale in patients with a CPS of ≥5; results were similar for the overall PRO analysis population. In CPS ≥5 and all randomly assigned populations, nivolumab plus chemotherapy reduced the risk of symptom deterioration versus chemotherapy, on the basis of FACT-Ga total score and GaCS; time to definitive deterioration was longer, and the risk of definitive deterioration in HRQoL was reduced with nivolumab plus chemotherapy across EQ-5D and most FACT-Ga measures (hazard ratio [95% CI] <1) | ||
520 | |a CONCLUSION: Compared with chemotherapy alone, first-line nivolumab plus chemotherapy showed stable or better on-treatment HRQoL in patients with advanced/metastatic non-HER2-positive GC/GEJC/EAC and also showed decreased risk of definitive HRQoL deterioration | ||
650 | 4 | |a Randomized Controlled Trial | |
650 | 4 | |a Journal Article | |
650 | 7 | |a Nivolumab |2 NLM | |
650 | 7 | |a 31YO63LBSN |2 NLM | |
700 | 1 | |a Xiao, Hong |e verfasserin |4 aut | |
700 | 1 | |a Blum, Steven I |e verfasserin |4 aut | |
700 | 1 | |a Elimova, Elena |e verfasserin |4 aut | |
700 | 1 | |a Cella, David |e verfasserin |4 aut | |
700 | 1 | |a Shitara, Kohei |e verfasserin |4 aut | |
700 | 1 | |a Ajani, Jaffer A |e verfasserin |4 aut | |
700 | 1 | |a Janjigian, Yelena Y |e verfasserin |4 aut | |
700 | 1 | |a Garrido, Marcelo |e verfasserin |4 aut | |
700 | 1 | |a Shen, Lin |e verfasserin |4 aut | |
700 | 1 | |a Yamaguchi, Kensei |e verfasserin |4 aut | |
700 | 1 | |a Liu, Tianshu |e verfasserin |4 aut | |
700 | 1 | |a Schenker, Michael |e verfasserin |4 aut | |
700 | 1 | |a Kowalyszyn, Ruben |e verfasserin |4 aut | |
700 | 1 | |a Bragagnoli, Arinilda Campos |e verfasserin |4 aut | |
700 | 1 | |a Bruges, Ricardo |e verfasserin |4 aut | |
700 | 1 | |a Montesarchio, Vincenzo |e verfasserin |4 aut | |
700 | 1 | |a Pazo-Cid, Roberto |e verfasserin |4 aut | |
700 | 1 | |a Hunter, Shannon |e verfasserin |4 aut | |
700 | 1 | |a Davenport, Eric |e verfasserin |4 aut | |
700 | 1 | |a Wang, Jinyi |e verfasserin |4 aut | |
700 | 1 | |a Kondo, Kaoru |e verfasserin |4 aut | |
700 | 1 | |a Li, Mingshun |e verfasserin |4 aut | |
700 | 1 | |a Wyrwicz, Lucjan |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Journal of clinical oncology : official journal of the American Society of Clinical Oncology |d 1986 |g 41(2023), 35 vom: 10. Dez., Seite 5388-5399 |w (DE-627)NLM012608777 |x 1527-7755 |7 nnns |
773 | 1 | 8 | |g volume:41 |g year:2023 |g number:35 |g day:10 |g month:12 |g pages:5388-5399 |
856 | 4 | 0 | |u http://dx.doi.org/10.1200/JCO.23.00170 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 41 |j 2023 |e 35 |b 10 |c 12 |h 5388-5399 |